AC
DMAA

Aristeia Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Aristeia Capital’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Sell
350,000
-531,716
-60% -$5.63M 0.05% 215
2026
Q1 		$9.24M Hold
881,716
– – 0.19% 100
2025
Q4 		$9.15M Hold
881,716
– – 0.2% 74
2025
Q3 		$9.06M Hold
881,716
– – 0.21% 69
2025
Q2 		$8.99M Sell
881,716
-18,284
-2% -$185K 0.24% 65
2025
Q1 		$9.02M Buy
+900,000
New +$9M 0.23% 59

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
RC
RLH Capital Great Neck, New York $209M AUM

Aristeia Capital's DMAA Position: Q2 2026 in Review

Aristeia Capital reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 60% in Q2 2026, selling an estimated $5.63M and leaving 350,000 shares worth $3.73M. The position accounts for 0.05% of the portfolio, ranked #215.

Aristeia Capital first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.24M in Q1 2026. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Aristeia Capital held 350,000 shares of Drugs Made In America Acquisition Corp worth $3.73M as of Q2 2026.
  • Aristeia Capital sold 531,716 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $5.63M.
  • Drugs Made In America Acquisition Corp made up 0.05% of Aristeia Capital's portfolio in Q2 2026, its #215 holding.
  • Aristeia Capital first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
  • Aristeia Capital's Drugs Made In America Acquisition Corp position peaked at $9.24M in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.